IE
COGT icon

Israel Englander’s Cogent Biosciences COGT Stock Holding History

Israel Englander’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,300
Closed -$158K – 5934
2024
Q4 		$158K Buy
+20,300
New +$202K ﹤0.01% 5379
2024
Q3 		– Sell
-103,400
Closed -$872K – 6144
2024
Q2 		$872K Buy
+103,400
New +$784K ﹤0.01% 4193
2024
Q1 		– Sell
-100,000
Closed -$588K – 6240
2023
Q4 		$588K Buy
+100,000
New +$766K ﹤0.01% 4542

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Israel Englander's COGT Position: Q2 2026 in Review

Israel Englander reduced its Cogent Biosciences (COGT) stake by 24% in Q2 2026, selling an estimated $9.96M and leaving 907,712 shares worth $35.1M. The position accounts for 0.01% of the portfolio, ranked #1149.

Israel Englander first reported a position in COGT in Q1 2018 and has held it in 28 quarters since. The position peaked at $45.9M in Q1 2026. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Israel Englander held 907,712 shares of Cogent Biosciences worth $35.1M as of Q2 2026.
  • Israel Englander sold 284,694 Cogent Biosciences shares in Q2 2026, an estimated $9.96M.
  • Cogent Biosciences made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1149 holding.
  • Israel Englander first reported a position in Cogent Biosciences in Q1 2018 and has held it in 28 quarters since.
  • Israel Englander's Cogent Biosciences position peaked at $45.9M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.